Skip to content
Disclosery

FCPM III SERVICES B.V.

Follow

13F filer, CIK 2013410, NAARDEN, Netherlands

FCPM III SERVICES B.V. reported $592,382,325 across 8 holdings for the quarter ended 2024-12-31, in a 13F-HR filed 2025-02-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-25-002356

Period
2024-12-31
Reported value
$592M
Holdings
8
Top 10 weight
100%
New
1
Sold out
0

Part of the filer group FCPM III SERVICES B.V.

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ASTRIA THERAPEUTICS INCnew+2,872,537$25.7M
BCYCadded+1,112,369$15.6M
ENGNadded+954,610$6.35M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
NAMSreduced-1,234,280-$31.7M
DYNreduced-491,223-$11.6M
REPLreduced-895,781-$10.8M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2024

Share positions as resolved from 13F-HR 0000950123-25-002356, largest first. % of portfolio is the value over $592,382,325, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
NAMSNEWAMSTERDAM PHARMA COMPANYQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 11,831,461 shares; 2024Q4: 10,597,181 shares 10,597,181$272M45.97%-1,234,280Timeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 5,954,069 shares; 2024Q4: 5,462,846 shares 5,462,846$129M21.73%-491,223Timeline
ENGNENGENE HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 8,677,951 shares; 2024Q4: 9,632,561 shares 9,632,561$64.1M10.81%+954,610Timeline
BCYCBICYCLE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,339,961 shares; 2024Q4: 3,452,330 shares 3,452,330$48.3M8.16%+1,112,369Timeline
REPLREPLIMUNE GROUP INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,866,449 shares; 2024Q4: 3,970,668 shares 3,970,668$48.1M8.12%-895,781Timeline
ASTRIA THERAPEUTICS INCASTRIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 2,872,537 shares 2,872,537$25.7M4.34%new
ACHILLES THERAPEUTICS PL-ADRACHILLES THERAPEUTICS PL-ADRQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,390,050 shares; 2024Q4: 2,390,050 shares 2,390,050$2.75M0.46%0
ENGNWENGENE HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,878,148 shares; 2024Q4: 2,878,148 shares 2,878,148$2.43M0.41%0Timeline

How Q4 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-25-002356 base2025-02-14acceptance time not in the bulk data set